Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Advanced Breast Cancer Brain Metastasis
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

A prospective, multicenter, observational cohort study to evaluate the efficacy and safety of a novel anti-tumor drug as a radiosensitizer in patients with advanced breast cancer brain metastasis.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Radiotherapy + Novel Anti-tumor Drug — 1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\] 2. Radiotherapy

Primary Outcomes

  • Intracranial Progression-Free Survival (24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-01
Completion: 2028-09-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Contact Information
Study Contact:
Fei Ma, Professor
13910217780
drmafei@126.com
MaFei Professor
13910217780
drmafei@126.com
Cancer Hospital, Chinese Academy of Medical Sciences
Interventions
  • Drug: Radiotherapy + Novel Anti-tumor Drug — 1. Novel anti-tumor drugs \[including: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc.\] 2. Radiotherapy
Study Locations (1 sites)
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, 100021 China
Eligibility Criteria
Inclusion Criteria: 1. Males or females who are at least 18 years of age on the day of signing the informed consent form. 2. Patients with advanced breast cancer that is inoperable and has metastasized to the brain, confirmed by histology or cytology. 3. Patients who are planned to receive, currently receiving, or have completed intracranial radiotherapy after discussion by a multidisciplinary team (MDT) at the stage of brain metastasis. 4. Patients who are planned or currently receiving a systemic treatment regimen with a novel anti-tumor drug selected by the physician, within 3 weeks before radiotherapy, during radiotherapy, or within 3 weeks after completion of radiotherapy. These drugs include: ADC drugs (such as T-DXd, T-DM1, etc.), CDK4/6 inhibitors, TKI drugs (such as Pyrotinib, Tucatinib, etc.), Novel chemotherapy drugs (such as Utidelone, Irinotecan liposomes, etc.), Bevacizumab, PD-1/PD-L1 inhibitors, etc. 5. Patients with a traceable medical history during the treatment period. 6. Patients who are able to sign the informed consent form to participate in the study. Exclusion Criteria: 1. The subject has leptomeningeal metastasis. 2. If the patient has concurrent brain metastasis, the neurological symptoms are too severe to cooperate with radiotherapy. 3. The subject has not signed the informed consent form. 4. Pregnant or breastfeeding women. 5. Other situations deemed by the investigator as unsuitable for inclusion in the study.
Conditions Breast Cancer Metastatic, Sentinel Lymph...
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: NIR-II probe (i.e ICG-CK) incubation solution — After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.

Primary Outcomes

  • Uptake of the dye by the tissue(i.e metastatic SLN) (1 year)
  • False positive rates of the NIR-II probe (ICG-CK) (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-01
Completion: 2026-12-01
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yunnan Cancer Hospital
Collaborators: Xiang'an Hospital of Xiamen University
Contact Information
Study Contact:
Junhong Chen, Postgraduate
86+17782287838
1145644908@qq.com
Weiling Chen, Doctor
86+13646039812
913208146@qq.com
Junhon Chen, Postgraduate
86+17782287838
1145644908@qq.com
Yunnan Cancer Hospital, Kunming, Yunnan 650118
Interventions
  • Diagnostic Test: NIR-II probe (i.e ICG-CK) incubation solution — After incubating the lymph node tissue with an optimal concentration of NIR-II probe for an appropriate amount of time, the tissue is washed with eluent, and then the fluorescence intensity of different tissues is detected to assess whether the tissue has cancer tissue invasion.
Study Locations (1 sites)
Yunnan Cancer Hospital, Kunming, Yunnan 650118, Kunming, Yunnan China
Eligibility Criteria
Inclusion Criteria: * Adult patients between 18-75 years of age * Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment * Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection; * Good operative candidate * Subject capable of giving informed consent and participating in the process of consent Exclusion Criteria: * Patients unable to participate in the consent process * Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc
Conditions Early Breast Cancer, Premenopausal Breas...
Phase PHASE3
Enrollment 3380
Locations 105 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Rationale: Around 70 to 80% of breast cancers are so-called "hormone-dependent" (HR+)/HER2-. For more than 50 years, studies have shown that chemotherapy and optimised hormonal treatments (hormone therapy), including a drug associated with ovarian suppression (OFS), improve survival in patients with these cancers, which are characterised by a high risk of relapse. However, younger patients suffer more side effects than older women, particularly from chemotherapy. This can affect their quality of life and reduce their ability to work. For post-menopausal women, genetic tests exist to assess whether chemotherapy is really necessary in addition to hormonal treatment. However, for high-risk premenopausal patients, chemotherapy is still systematically recommended, as no study has proved that it can be safely avoided. Clinical trials based on risk stratification using genetic tests have not been conclusive, but the majority of premenopausal women included had not received optimal hormone treatment. It is possible that the beneficial effect of chemotherapy is partly due to the artificial menopause it induces. Some experts believe that, for patients with a high clinical risk but a low genetic risk, an optimised hormonal treatment (drug + OFS) could suffice, without the need for chemotherapy. Objectives: Main objective: The aim of the study is to determine whether the use of a genetic test (Prosigna®) to decide whether or not to administer chemotherapy produces results as good as standard treatment (systematic chemotherapy) in premenopausal women with hormone-dependent (HR+) breast cancer/HER2-, by assessing their risk of cancer recurrence. The secondary objectives include verifying whether, in patients with a low Prosigna® score (around 70% of cases), optimised hormonal treatment (including suppression of ovarian function) is as effective as chemotherapy combined with hormonal in treatment preventing cancer recurrence. The study also seeks to compare the efficacy of treatment Prosigna®-guided versus systematic chemotherapy in terms of recurrence and quality of life, as well as economic aspects. Finally, the aim is to understand patients' concerns about the concept of reducing treatment (therapeutic de-escalation) and the way in which this information is communicated to them. The primary endpoint of the study is to measure the time elapsed between the start of participation in the study and the appearance of an event indicating a return of the cancer. This includes the return of cancer in the same breast or neighbouring areas, the spread of cancer to other parts of the body, the appearance of new cancer in the other breast or death from any cause. Trial Population: The study includes women major premenopausal diagnosed with invasive, hormone receptor-positive (ER+) and HER2-negative breast cancer. Patients must have undergone breast and axillary surgery recent and have a tumour sample suitable for analysis by the testProsigna® . They must be able…

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone — In this experimental arm, the treatment is driven by the score of the Prosigna test. If the score is superior to 60, the patient is considered at hight risk so the patient will receive chemo-endocrine therapy. If the result is under or equal to 60, only endocrine therapy will be prescribed to the patient.
  • Drug: In the control arm, the treatment will be as standard of care : chemo-endocrine therapy — Standard treatment: Chemotherapy followed by endocrine therapy

Primary Outcomes

  • invasive breast cancer free survival (IBCFS) (Time from the date of randomization to the date of the first event (ipsilateral loco-regional invasive breast or distant breast cancer recurrence, contralateral new invasive primary breast cancer or death from any cause), assessed up to 120 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-06-26
Completion: 2038-08-15
Eligibility
Age: 35 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 3380 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: UNICANCER
Collaborators: University of Warwick
Principal Investigators:
  • Ines Vaz-Luis (PRINCIPAL_INVESTIGATOR) - Gustave Roussy, Cancer Campus, Grand Paris
Contact Information
Study Contact:
Aure Vanhecke
+33662962532
a-vanhecke@unicancer.fr
Vanhecke
Dr Marti
Centre Hospitalier d'Auxerre
Interventions
  • Drug: test-directed treatment: allocated treatment will depend on the PAM50 score result (centrally assessed) : chemo-endocrine therapy or endocrine therapy alone — In this experimental arm, the treatment is driven by the score of the Prosigna test. If the score is superior to 60, the patient is considered at hight risk so the patient will receive chemo-endocrine therapy. If the result is under or equal to 60, only endocrine therapy will be prescribed to the patient.
  • Drug: In the control arm, the treatment will be as standard of care : chemo-endocrine therapy — Standard treatment: Chemotherapy followed by endocrine therapy
Study Locations (105 sites)
Institut Jules Bordet, Brussels, 1070 Belgium
Cliniques Universitaires Saint-Luc, Brussels, 1200 Belgium
Grand Hôpital de Charleroi, Charleroi, B-6060 Belgium
CHU Helora Hôpital de La Louvière - Site Jolimont, Haine-Saint-Paul, 7100 Belgium
CHU UCL Namur - Site Sainte Elisabeth, Namur, 5000 Belgium
Clinique Saint Pierre, Ottignies, 1340 Belgium
CHR Verviers, Verviers, 4800 Belgium
Centre Hospitalier d'Auxerre, Auxerre, 89000 France
Sainte Catherine - Institut du Cancer Avignon-Provence, Avignon, 84918 France
Centre Hospitalier de la Côte Basque, Bayonne, 64100 France
Eligibility Criteria
Inclusion Criteria: 1. Patient must have signed a written informed consent prior to any trial specific procedures. When the patient is physically unable to give their written consent, a trusted person of their choice, independent from the investigator or the sponsor, can confirm in signing the patient's consent; 2. . Premenopausal defined by patient that are not post-menopaused 3. Female 4. Age ≥ 35 years 5. Diagnosis of invasive HR-positive (ER≥10% of tumour cells stained positive and any PR expression) HER2-negative (IHC score 0-1+ or 2+ with negative/non-amplified ISH) invasive breast cancer; ER and HER2 determination will be assessed according to latest ASCO/CAP or national guidelines; 6. Breast and axillary surgery completed ≤ 12 weeks from study entry and randomization; 7. Availability of a Formalin-Fixed Paraffin-Embedded (FFPE) tumour sample from surgery to perform Prosigna® analysis or slides. Note: in case of receipt of neoadjuvant endocrine therapy the Prosigna® test must be done on the baseline biopsy. Performing the test on the surgical piece or on on-treatment biopsy is not permitted. 8. Tumour size and axillary lymph node status. One of the following must apply: 1. 1-3 lymph nodes involved AND any invasive tumour size. 2. node negative (including micrometastases in at least 1 node \[i.e. deposit \>0.2-2mm diameter\]) AND invasive tumour size ≥ 50mm. 9. Multiple ipsilateral breast cancers are permitted provided that at least one tumour meets the tumour size and axillary lymph node entry criteria, and none meet any of the exclusion criteria. 10. Bilateral breast cancers are permitted provided the tumour(s) in one breast meets the eligibility criteria and the other, contralateral tumour is not ER negative and/or HER2 positive and not clinically significant, defined by both of the following: 1. The contralateral tumour does not fulfil the tumour size and lymph node eligibility criteria required for trial entry; i.e. the following are not acceptable: .i. presence of lymph node macro-metastases; .ii. tumour size ≥50mm when there is no lymph node involvement. 2. The treating physician does not consider that the characteristics of the contralateral tumour alone justify consideration of adjuvant chemotherapy. 11. Fitness to receive adjuvant chemotherapy, as judged by the treating physician; 12. Short term pre-surgical treatment with endocrine therapy, including in combination with non-cytotoxic agents, is allowed providing that the duration of treatment did not exceed 8 weeks; 13. Patients affiliated with or a beneficiary of the local social security system, health social security system, or other local regulatory requirements 14. Patients must agree to use adequate contraception methods for the duration of study treatment and for the duration specified in the SmPC after completing the treatment, unless agreed with the treatment physician the safety of attempt a pregnancy, which could be possible after at least 18 months of endocrine therapy. Note : patient with extracapsular nodular transgression are eligible. NOTE: If neoadjuvant endocrine therapy was received, the Prosigna® test must be realized on the baseline biopsy. Performing the test on the surgical specimen or on biopsy taken during treatment is not permitted. NOTE: Re-excision or complementary mastectomy for close/positive surgical margins should be postponed after chemotherapy completion, if chemotherapy is given; breast reconstruction is allowed after trial entry. NOTE: The use of approved adjuvant targeted agents (abemaciclib, ribociclib and olaparib) combined to adjuvant endocrine therapy is allowed according to local practice recommendations and availability. Exclusion Criteria: * 1\. Postmenopausal women. Women who fulfil the following criteria at trial entry will be considered postmenopausal: 1. Age \>45 and natural amenorrhoea of at least 1 year's duration. 2. Bilateral surgical oophorectomy. 3. For amenorrhoea not fulfilling the above criteria the diagnosis of postmenopausal status should be supported by hormone measurement: FSH levels must be \> 25IU/L with low oestradiol (i.e. within the locally defined postmenopausal range), in the event of doubt measured on 2 occasions preferably 4-6 weeks apart. This applies to women who have undergone hysterectomy without bilateral surgical oophorectomy and are age \<60; those ≥60 may be considered postmenopausal. NOTE: Hormonal contraception will suppress FSH and oestradiol levels. In those taking oral contraception, levels will recover rapidly on discontinuation. Depo-Provera injectable contraception lasts many months: all women receiving this agent should be considered premenopausal. 2\. Stage IV breast cancer; 3. Start of adjuvant systemic treatment (except for neoadjuvant endocrine therapy for a duration ≤ 8 weeks) before trial entry\*; 4. Previous diagnosis of malignancy except: <!-- --> 1. Previous ductal carcinoma in situ (DCIS) or pleomorphic lobular carcinoma in situ (LCIS) of the breast managed by local treatment only; 2. Previous in situ carcinoma as defined by the International Classification of Diseases for Oncology (ICD-O) including basal cell carcinoma of skin and cervical intraepithelial neoplasia; 3. Previous invasive malignancy managed by local treatment only AND disease-free for at least 10 years. 5\. Patients enrolled in another therapeutic trial within 30 days of inclusion; 6. Presence of concomitant medical and/or psychiatric comorbidities and/or social problems that might prevent informed consent, treatment compliance or follow up; 7. Person deprived of their liberty or under protective custody or guardianship. 8\. Pregnant women or women who are breast-feeding at inclusion. 9. Patients unwilling or unable to comply with the protocol for the duration of the study including scheduled visits, treatment plan, laboratory tests and other study procedures because of geographic, familial, social, or psychological reasons. \*Trial entry is dated from of the date the participant signs the consent form or provides remote verbal consent, whichever is earlier.
Conditions Diabete Type 2
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to investigate the clinically convenient dynamic and static measurement parameters to identify related risk factors of developing high peak plantar pressure during walking in the type-2 diabetic patients, and then establish a predictive model to estimate the likelihood of excessive plantar pressure. The main question it aims to answer is: Which clinical measurements may be used as the predictors that increased peak plantar pressure in the type-2 diabetic patients? Participants taking the examinations will understand their own clinally meaningful measurements related to their plantar pressure during walking. Further thorough analysis will be employed to develop a predictive model, aiming to provide potential improvement strategies for preventing diabetic foot ulcers in the future.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Primary Outcomes

  • plantar pressure (Day 1: a single time point)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-10-01
Completion: 2026-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: China Medical University Hospital
Collaborators: China Medical University, Taiwan
Contact Information
Study Contact:
Hsiu-Chen Lin, PhD
+886422053366
hclin@mail.cmu.edu.tw
Ming-Chen Hsieh, MD, PhD
+886-3-5580-558
Hsiu-Chen Lin
0422053366
hclin@mail.cmu.edu.tw
China Medical University, Department of Physical Therapy
Interventions
N/A
Study Locations (1 sites)
China Medical University, Department of Physical Therapy, Taichung, Taiwan 406040 Taiwan
Eligibility Criteria
Inclusion Criteria: * diagnosed with type 2 diabetes, at least for five years * aged older than 18 years * walk independently for at least 10 meter without any assistive device Exclusion Criteria: * severe deformity in the foot or lower extremity * significant neuropathic or surgical diseases that affect normal walking function * cognitive dysfunction * active foot ulcer
Conditions Type 2 Diabetes Mellitus
Phase PHASE3
Enrollment 800
Locations 149 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron alone or in combination with dapagliflozin compared with placebo in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Elecoglipron — Elecoglipron is administered orally once daily.
  • Drug: Dapagliflozin — Dapagliflozin administered orally once daily.
  • Drug: Elecoglipron-matched placebo — A placebo matching elecoglipron, administered orally once daily.
  • Drug: Dapagliflozin-matched placebo — A placebo matching dapagliflozin, administered orally once daily.

Primary Outcomes

  • Change from baseline in Hemoglobin A1c (HbA1c) (Baseline to Week 40)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-07-06
Completion: 2028-07-14
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
  • Drug: Elecoglipron — Elecoglipron is administered orally once daily.
  • Drug: Dapagliflozin — Dapagliflozin administered orally once daily.
  • Drug: Elecoglipron-matched placebo — A placebo matching elecoglipron, administered orally once daily.
  • Drug: Dapagliflozin-matched placebo — A placebo matching dapagliflozin, administered orally once daily.
Study Locations (149 sites)
Research Site, Birmingham, Alabama 35233 United States
Research Site, Daphne, Alabama 36526 United States
Research Site, Lomita, California 90717 United States
Research Site, Los Alamitos, California 90720 United States
Research Site, San Diego, California 92111 United States
Research Site, Walnut Creek, California 94598 United States
Research Site, Englewood, Colorado 80110 United States
Research Site, Bridgeport, Connecticut 06606 United States
Research Site, Jacksonville, Florida 32256 United States
Research Site, Orlando, Florida 32801 United States
Eligibility Criteria
Inclusion Criteria: * Diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 90 days prior to screening * T2DM inadequately managed with lifestyle management alone or on stable treatment with other background glucose-lowering medication * HbA1c value of ≥ 7% to ≤ 10.5% (53 to 91.3 mmol/mol) * Body mass index (BMI) of ≥ 23 kg/m2 at screening * Stable body weight (self-reported or documented) for 90 days prior to screening Exclusion Criteria: * Type 1 diabetes, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma * Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema * Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms * Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying * History of acute or chronic pancreatitis * Severe congestive heart failure (New York Heart Association IV) * History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Conditions Obesity, Overweight (Without Type 2 Diab...
Phase PHASE3
Enrollment 2539
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Tirzepatide — (once-weekly SC injection; doses 5/10/15 mg)
  • Drug: Placebo — (once-weekly SC injection)
  • Behavioral: Reduced-calorie diet — increased physical activity counseling

Primary Outcomes

  • Mean percent change in body weight from randomization (72 Weeks)
  • Percentage of participants achieving ≥5% body weight reduction from randomization (72 Weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2026-02-02
Completion: 2028-03-17
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2539 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hudson Biotech
Contact Information
Study Contact:
Seni S Lu, Phd
+86 13076790030
Seni-Lu@beijing-biotech.com
Zhen J Peng, Phd
+86 13076790039
Zhen-Peng@beijing-biotech.com
Peking University Shenzhen Hospital
Interventions
  • Drug: Tirzepatide — (once-weekly SC injection; doses 5/10/15 mg)
  • Drug: Placebo — (once-weekly SC injection)
  • Behavioral: Reduced-calorie diet — increased physical activity counseling
Study Locations (1 sites)
Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036 China
Eligibility Criteria
Inclusion Criteria: * BMI ≥30 kg/m², OR BMI ≥27 kg/m² with ≥1 weight-related comorbidity (e.g., hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease) * History of at least one unsuccessful dietary effort to lose weight (self-reported) * Investigator judges participant capable and willing to self-inject (or have assistance), follow lifestyle advice, maintain a diary, and complete questionnaires * Age ≥18 years * Meets protocol contraception/pregnancy criteria (as applicable) and provides written informed consent Exclusion Criteria: * Type 1 or type 2 diabetes, history of ketoacidosis/hyperosmolar state, or screening labs diagnostic of diabetes * Recent significant weight change (\>5 kg within 3 months prior to screening) * Prior/planned bariatric surgery; recent/ongoing endoscopic or device-based obesity therapies * Severe renal impairment (eGFR \<30 mL/min/1.73 m²) * Clinically significant gastric emptying abnormality or chronic use of drugs that directly affect GI motility * History of chronic or acute pancreatitis * Clinically significant thyroid abnormalities at screening (e.g., TSH outside protocol range) or anticipated need to initiate thyroid replacement during study * Obesity due to other endocrinologic disorders (e.g., Cushing syndrome) or monogenic/syndromic obesity (e.g., MC4R deficiency, Prader-Willi syndrome) * Significant unstable major depressive disorder/severe psychiatric disorder, lifetime suicide attempt, or concerning suicidality screening (PHQ-9/C-SSRS criteria) * Uncontrolled hypertension; recent major cardiovascular events; NYHA class IV heart failure * Active or significant liver disease or certain elevated liver tests at screening (per protocol thresholds) * Elevated calcitonin above protocol thresholds; personal/family history of medullary thyroid carcinoma or MEN2 * Active/untreated malignancy or remission \<5 years (with specified exceptions) * Any other condition contraindicating GLP-1 receptor agonist therapy
Conditions Hypoxia, Altitude, Hypoxia, Normobaric H...
Phase NA
Enrollment 18
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

More and more people are engaging in sports in the mountains, including individuals with heart or lung diseases. At the same time, such diseases are becoming more common in Switzerland. At high altitude, less oxygen is available, which places stress on the body-particularly on the heart, which has to pump blood through the lungs. How the heart, especially the right ventricle, in people with asthma responds to this stress is still not well understood. Therefore, this study investigates how the heart responds to simulated altitudes of 2,500 m and 4,000 m, both at rest and during light physical activity in patients with asthma. The primary objective is to assess how right ventricular function changes under conditions of reduced oxygen availability. In addition, vital signs, changes in blood gases, oxygen levels in blood and tissue and shortness of breath are assessed. The "altitude" is simulated using a special gas mixture that participants inhale. Participants undergo three altitude conditions (490, 2,500, and 4,000 m above sea level). The order of the altitude conditions is assigned at random. The aim is to better understand how the right ventricle and other parameters respond to low-oxygen conditions and how affected patients can be better supported in the future.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Diagnostic Masking/blinding: Triple

Interventions / Regimen

  • Other: Normobaric Hypoxia — Normobaric hypoxia according to 408m (control/normobaric normoxia), 2500 m and 4000 m above sea-level at rest for 1 hour and at low intensity cycling for 10 minutes (5 min 30 W, 5 min 60 W).

Primary Outcomes

  • Right ventricular free wall strain (It will be assessed once at baseline in rest and during each condition three times: Once after 1 hour in the specific condition at rest, then during the 5 min of 30 Watt cycling and during the 5 min of 60 Watt cycling.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-26
Completion: 2030-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 18 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mona Lichtblau
Principal Investigators:
  • Mona Lichtblau (PRINCIPAL_INVESTIGATOR) - University of Zurich
Contact Information
Study Contact:
Mona Lichtblau, PD Dr. med.
+41 442552220
mona.lichtblau@usz.ch
Carmen Wick, Cand. PhD
+41 43 253 44 05
carmen.wick@usz.ch
Mona Lichtblau, PD Dr. med.
mona.lichtblau@usz.ch
Consultant Clinic of Pulmonology, University Hospital of Zurich
Interventions
  • Other: Normobaric Hypoxia — Normobaric hypoxia according to 408m (control/normobaric normoxia), 2500 m and 4000 m above sea-level at rest for 1 hour and at low intensity cycling for 10 minutes (5 min 30 W, 5 min 60 W).
Study Locations (1 sites)
Consultant Clinic of Pulmonology, University Hospital of Zurich, Zurich, Canton of Zurich 8091 Switzerland
Eligibility Criteria
Inclusion Criteria: * Signed informed consent * Diagnosed and well controlled asthma bronchiale * 18-80 years (age group young: 18-39.99 years / age group older: 40-80 years) * All sex and genders * Living \<800m and without altitude exposure \> 2500 m and \> 24h within the last three weeks Exclusion Criteria: * \<18, \>80 years old * Any other diagnosed cardiopulmonary condition including past HAPE * Other clinically significant severe concomitant disease states (e.g. renal, hepatic dysfunction, etc.) * Inability to follow the procedures of the study due to language problems, psychological neurological disorders or orthopaedic disorders * Participants permanently living \>800m and altitude exposure \> 2500 m and \>24h within the last three weeks * Pregnancy: Participants will be asked if pregnant or not, no screening for undetected pregnancy * Lactating women * Participation in other study with active treatment
Conditions Asthma
Phase NA
Enrollment 180
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the ATHENA Project is to test a mobile health intervention to help African American young adults better manage their asthma. The program has four components: 1) a web-based, mobile asthma program delivered to participants' mobile device, 2) meetings with an asthma nurse via video conference, 3) text messaging, and 4) physical activity tracking. Participants will be randomly assigned to one or more of these components to better meet the needs of young adults with asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Motivational Enhancement System (MES) — MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
  • Behavioral: Supportive Accountability (SA) — Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
  • Behavioral: Text Messaging (SMS) — SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
  • Behavioral: Physical Activity Tracking (PAT) — All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.

Primary Outcomes

  • Asthma Control Test (ACT) (Change from baseline at 3, 6, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-08-01
Completion: 2027-05-31
Eligibility
Age: 18 Years – 30 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Alan Baptist, MD. (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Alan Baptist, MD.
734-936-5634
abaptist@med.umich.edu
Muzhda Hashmi, BS
734-232-6868
hashmim@med.umich.edu
Karen MacDonell, Ph.D
karen.macdonell@med.fsu.edu
Florida State University
Interventions
  • Behavioral: Motivational Enhancement System (MES) — MES is an eHealth application and focuses on asthma management behaviors with feedback on asthma symptoms, physical activity, adherence, and tailored education. The program is interactive and tailored to each participant by (1) allowing participants to choose barriers/goals related to their asthma care and (2) by sending personalized feedback based on participant daily diary responses. MES consists of 4 sessions delivered over the course of 10 weeks within 10 smaller 5-10 minute blocks.
  • Behavioral: Supportive Accountability (SA) — Supportive accountability (SA) is an asthma management intervention delivered by asthma nurses trained in motivational interviewing skills (e.g., open-ended questions around change talk, affirmations) via participants' personal mobile devices (e.g., Skype, FaceTime, voice calls, and SMS). The theory underlying SA is that education and behavior change are most impactful when delivered by a knowledgeable yet supportive authority figure (i.e. nurse).
  • Behavioral: Text Messaging (SMS) — SMS will target asthma knowledge. SMS messages will be sent via CIAS 3.0 to participants' personal mobile devices with facts about asthma management, links to educational web content, and videos providing information about living with asthma. Information covered includes 'What is asthma,' 'What is an asthma attack,' 'What causes an asthma attack,' 'How is asthma treated,' 'Asthma and weather,' 'Using an inhaler,' 'Using a spacer,' and 'Asthma Action Plans.'
  • Behavioral: Physical Activity Tracking (PAT) — All participants will be provided a wearable physical activity tracking device, which will allow them to accurately track exercise and total steps each day. Through PAT, users will be able to set daily goals and attain motivation to continue asthma management. For individuals randomized to groups that also include MES or SA, those programs will incorporate PAT data that is remotely transmitted, to facilitate asthma management motivation.
Study Locations (3 sites)
Florida State University, Tallahassee, Florida 32306 United States
University of Michigan, Ann Arbor, Michigan 48106 United States
Wayne State University, Detroit, Michigan 48202 United States
Eligibility Criteria
Inclusion Criteria: * African American, 18-30 years of age, uncontrolled asthma (defined by a score of less than 19 on the ACT), own or have access to a cell phone for the duration of the study, have a primary care physician (PCP) Exclusion Criteria: * Significant cardiopulmonary disease (including chronic obstructive pulmonary disease), a greater than 20 pack per year smoking history, developmental delay or mental illness such that participation in the program would not be possible, pregnancy
Conditions Lung Cancer, Lung Infection, COPD, Bronc...
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) marker molecules. This model aims to accurately diagnose mutiple pulmonary diseases. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose several common pulmonary diseases. 2. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in diagnose more pulmonary diseases.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system — Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID

Primary Outcomes

  • The diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in the diagnosis of several common pulmonary diseases. (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-06-30
Completion: 2027-06-30
Eligibility
Age: 18 Years – 100 Years
Sex: ALL
Volunteers: true
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ChromX Health
Collaborators: The First Affiliated Hospital of Guangzhou Medical University, First People's Hospital of Foshan, Sichuan Cancer Hospital and Research Institute, Liwan District Central Hospital, Shanghai Chest Hospital, Peking Union Medical College Hospital, Guangzhou Development Zone Hospital, Huangpu District Hongshan Street Community Health Service Center, Huangpu District Chinese Medicine Hospital, Fifth Affiliated Hospital of Guangzhou Medical University, Huangpu District Jiufo Street Community Health Service Center, Huangpu District Xinlong Town Central Hospital, Huangpu District Yonghe Street Community Health Service Center, Huangpu District Lianhe Street Second Community Health Service Center
Principal Investigators:
  • Jianxing He, MD (STUDY_CHAIR) - The First Affiliated Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Hengrui Liang, MD
+86 15625064712
hengrui_liang@163.com
Hengrui Liang, MD
+86 15625064712
hengrui_liang@163.com
The First Affiliated Hospital of Guangzhou Medical University
Interventions
  • Other: Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system — Exhaled breath samples from these participants will be collected and analyzed to detect volatile organic compound molecules in human exhaled breath by GC-MS and μGC-PID
Study Locations (1 sites)
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510140 China
Eligibility Criteria
Inclusion Criteria: * Males or females, age must be 18 years old or above. * Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data. * Patients must have a clear clinical diagnosis. * All participants must sign a written informed consent form. Exclusion Criteria: * Pregnant women. * Individuals with a history of cancer other than lung disease. * Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants. * Individuals with other severe organic diseases or mental illnesses. * Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc. * Any other condition that researchers deem unsuitable for participation in this clinical trial.
Conditions Progressive Multiple Sclerosis, Depressi...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Virtual Reality — Participant will have 8 weeks of immersive VR nature-based experiences. Participants are expected to use the VR headset three times per week. Headsets will contain a prototype application (app) developed by Explore POV. This app will include approximately one hour of footage showcasing 15-25 different nature experiences, that will shuffle every time participants access it. Participants will have the option to choose between 5, 10, or 15 minutes, sessions while answering weekly surveys regarding their experiences.
  • Other: Standard care — Participants that are in the randomized groups will continue on antidepressants or psychotherapy during the study per their standard care. Participants in the non-randomized group don't receive any treatment for their depression and will continue not to receive anything for this during the study.

Primary Outcomes

  • Changes to the Patient-Reported Outcomes Measurement Information System (PROMIS) Depression short form 8b scores (Baseline, 9-10 weeks and 20-21 weeks)
  • Virtual Reality (VR) Sessions completed over 8 weeks (8-week VR intervention)
  • Qualitative feedback on the VR Neuroscience Questionnaire during the intervention (groups 1 and 3) (1-8 weeks (during VR))
  • Qualitative feedback with Semi-structured interviews for participants that received VR (Weeks 9-10, Weeks 20- 21)
  • Enrollment rate (Recruitment period (2 years))
  • Retention rates (Baseline - 21 weeks)
  • Adherence to VR intervention (8-week VR intervention)
  • Dropout reasons (Baseline - 21 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-15
Completion: 2027-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Michigan
Collaborators: Apple Inc., The International Organization of Multiple Sclerosis Nurses Inc
Principal Investigators:
  • Hala Darwish, PhD (PRINCIPAL_INVESTIGATOR) - University of Michigan
Contact Information
Study Contact:
Zee Petrie
734- 764- 5249
petrieli@umich.edu
Zee Petrie
734- 764- 5249
petrieli@umich.edu
University of Michigan
Hala Darwish, PhD
University of Michigan
Interventions
  • Device: Virtual Reality — Participant will have 8 weeks of immersive VR nature-based experiences. Participants are expected to use the VR headset three times per week. Headsets will contain a prototype application (app) developed by Explore POV. This app will include approximately one hour of footage showcasing 15-25 different nature experiences, that will shuffle every time participants access it. Participants will have the option to choose between 5, 10, or 15 minutes, sessions while answering weekly surveys regarding their experiences.
  • Other: Standard care — Participants that are in the randomized groups will continue on antidepressants or psychotherapy during the study per their standard care. Participants in the non-randomized group don't receive any treatment for their depression and will continue not to receive anything for this during the study.
Study Locations (1 sites)
University of Michigan, Ann Arbor, Michigan 48109 United States
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of progressive Multiple Sclerosis (MS, primary or secondary) by a neurologist or an MS center * Patient-Reported Outcomes Measurement Information System (PROMIS) Depression T-scores \>55 at baseline * Ability to provide informed consent and participate in VR sessions at home * For Some Participants (Groups 1 and 2) currently receiving antidepressant or psychotherapy treatments (Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), or psychotherapy) for the management of depression Exclusion Criteria: * Severe cognitive impairments or visual deficits that may interfere with VR use, including contraindications like agoraphobia, claustrophobia, or motion sickness * Current participation in other clinical trials targeting depression * Severe psychiatric conditions that require hospitalization, or suicidal ideation, passive or active, psychosis, or active substance and alcohol abuse (score greater than 1 on CAGE (Cut down, Annoyed, Guilty, Eye-opener) Adapted to Include Drugs (CAGE-AID)) * Another neurological or autoimmune disease per protocol * Participants that require vision correction, unless that vision correction is mild (± 1), or the participant has prescription contact lenses.
Conditions Heart Failure
Phase NA
Enrollment 100
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This study will test the effectiveness of a culturally-sensitive, telephone-based, tailored problem-solving intervention to improve physical and mental health in Veterans with heart failure (HF). Veterans will be recruited from VA clinics throughout the United States. As a component of this study, Veterans will partner with a registered nurse for a 12-week telehealth program that includes 8 telephone sessions. Follow-up data will be collected at 3-months (post intervention) and 6-, 12-, and 18-months to examine sustainability of intervention effect.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Care-HF — Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.

Primary Outcomes

  • Heart Failure Self-care (baseline)
  • Heart Failure Self-care (3-months)
  • Heart Failure Self-care (6-months)
  • Heart Failure Self-care (12-months)
  • Heart Failure Self-care (18-months)
  • Heart Failure Symptoms (baseline)
  • Heart Failure Symptoms (3-months)
  • Heart Failure Symptoms (6-months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-31
Completion: 2026-09-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Florida State University
Collaborators: US Department of Veterans Affairs
Principal Investigators:
  • Lucinda J Graven, PhD (PRINCIPAL_INVESTIGATOR) - Florida State University College of Nursing
Contact Information
Study Contact:
Lucinda J Graven, PhD
850-644-5601
lgraven@fsu.edu
Kimberly Phillips
Kimberly.Phillips1@va.gov
VA Clinic - Gainesville
November Poulin
November.Poulin@va.gov
VA Clinic - Togus
Interventions
  • Behavioral: Care-HF — Participants will be trained to use a 5-step problem-solving process based on the Theory of Social Problem-Solving (TSPS) to manage HF-related problems over 12-weeks. The core belief of TSPS is effective problem-solving requires a positive problem orientation (i.e., viewing problems as a challenge versus a threat) and elicits rational problem-solving versus avoidance or impulsivity/carelessness. Problem-solving follows from a positive problem orientation and involves accurate problem identification, generation of appropriate potential solutions, active decision-making, and solution implementation and evaluation. The goal of this intervention is to move participants toward a positive problem orientation and use of rational problem-solving strategies that support greater physical and mental health.
Study Locations (4 sites)
VA Clinic - Gainesville, Gainesville, Florida 32608 United States
VA Clinic - Togus, Togus, Maine 04330 United States
VA Clinic - Durham, Durham, North Carolina 27705 United States
VA Clinic - Providence, Providence, Rhode Island 02908 United States
Eligibility Criteria
Inclusion Criteria: * Age 18 years of age or older * US Veteran * Diagnosed with heart failure (reduced or preserved ejection fraction) * Able to read, speak, and understand English * Reliable telephone access Exclusion Criteria: • History of cognitive dysfunction
Conditions Pain, Sleep, Anxiety, Depression, Epilep...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-08
Study Details Design, interventions, and primary outcomes

About This Study

This prospective observational study aims to describe the effectiveness of MC on pain, epilepsy, sleep and /or anxiety/depression in a cohorts of patients authorized to use MC, using pre-defined, validated self assessment scales.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Medical Cannabis — Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements

Primary Outcomes

  • Change in pain intensity from baseline to week 24 post-authorization of MC: Measured using the numerical rating scale (NRS). (Baseline, 6, 12, 18 (if applicable) and 24 weeks)
  • Change in pain interference from baseline to week 24 post-authorization of MC: Measured using the Patient-Reported Outcomes Measurement Information System (PROMIS)-Pain Interference short form 6a. (Baseline, 6, 12, 18 (if applicable) and 24 weeks)
  • Sleep: Change in the Pittsburgh Sleep Quality Index (PSQI) from baseline to week 24 post-authorization of MC (Baseline, 6, 12, 18 (if applicable) and 24 weeks)
  • Anxiety: Change in the symptoms from baseline to week 24 post-authorization of MC; Measured using Generalized Anxiety Disorder 7-item scale (GAD-7). (Baseline, 6, 12, 18 (if applicable) and 24 weeks)
  • Depression: Change in the symptoms from baseline to week 24 post-authorization of MC. Measured by Patient Health Questionnaire 9 item scale (PHQ-9). (Baseline, 6, 12, 18 (if applicable) and 24 weeks)
  • Change in quality of life from baseline to Week 24: Measured using EuroQuol-5D-3-level health questionnaires(EQ-5D-3L) assessment scale. (Baseline, 6, 12, 18 (if applicable) and 24 weeks)
  • Epilepsy: change in seizure frequency for multiple different seizure types from baseline to Week 24 (Baseline, 6, 12, 18 and 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-07-15
Completion: 2028-07
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Health Network, Toronto
Collaborators: Avicanna Inc
Principal Investigators:
  • Hance Clarke, MD, PhD (PRINCIPAL_INVESTIGATOR) - Toronto General Hospital, UHN
Contact Information
Study Contact:
Sonal Thaker
416-340-4800 X 4251
sonalben.thaker@uhn.ca
Sonal Thaker
4163404800
Sonalben.thaker@uhn.ca
Toronto General Hospital, UHN
Interventions
  • Other: Medical Cannabis — Verified medical cannabis products available within the current real-world study conform to Health Canada testing requirements
Study Locations (1 sites)
Toronto General Hospital, UHN, Toronto, Ontario M5G 2C4 Canada
Eligibility Criteria
Inclusion Criteria: * Subjects (≥19 years of age) who are MC-naïve or -experienced with a medical authorization for MC provided by a prescribing health care practitioner and who have provided informed consent * Primary therapeutic indications for MC use: pain, epilepsy, sleep, and/or anxiety/depression. * Subjects agree to use verified products and refrain from using any other cannabis products, either medical or recreational, during the duration of the study Exclusion Criteria: * Concomitant use of illicit drugs * Concomitant use of recreational cannabis